News
Slideshow
‘Coercive and chaotic:’ 7 takeaways on Trump’s most-favored nation drug pricing plan for physicians
In part two of MJH Life Sciences’ three-part series, experts dissect President Trump’s most-favored nation executive order, warning that its use of tariffs and foreign price benchmarks could upend drug markets and test the limits of federal authority.
On Oct. 8, 2025, Medical Economics and its parent company, MJH Life Sciences®, convened a diverse panel of legal, policy and industry experts for the second installment in MJH's webinar series on drug pricing reform, titled “Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”
The discussion delved into President Donald J. Trump’s MFN executive order, unpacking its implications for Medicare, pharmacy benefit managers, hospitals, insurers and — most critically — patient access to care.
With aggressive use of tariffs, potential constitutional challenges and sweeping disruptions looming, physicians are on the front lines of how this policy will reshape drug access, innovation and practice economics.
To watch the full webinar on demand, register here.
Missed Part 1 of the series? Register here to watch Part 1 on demand, or read the key takeaways from Part 1 here.
Above are 7 takeaways for physicians from the webinar.
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
